There is a great need for portable and rapid methods to improve screening of patients with brain injuries. Pre-hospital diagnosis can save lives, minimise disability and thereby save money for society.
Medfield Diagnostics AB (publ) aims to improve diagnosis of brain injuries. Early diagnosis will enable faster treatment, minimising unnecessary suffering, improving outcomes and lead to cost savings for healthcare and society.
Medfield develops microwave based systems intended for use in both in pre-hospital and hospital settings, primarily to screen patients with brain injuries.
Medfield Diagnostics Aktiebolag (”Medfield” eller ”Bolaget”) har genomfört en företrädesemission av units om cirka 16,7 MSEK, som avslutades den 6 december 2019. Företrädesemissionen tecknades till cirka 45,6 MSEK, motsvarande en teckningsgrad… läs mer
Medfield Diagnostics Aktiebolag (”Medfield” eller ”Bolaget”) har slutfört den företrädesemission av units bestående av aktier och teckningsoptioner, som beslutades av bolagsstämman den 13 november 2019. Teckningstiden löpte från och med… läs mer
On September 10, Medfield Diagnostics AB hosted a Health Minister’s visit from Australia NSW. The Minister and his delegation were particularly interested in discussing Medfield’s opportunities to collaborate in the development of pre-hospital stroke and trauma care and the use of the Medfield MD100 system.
The background to the visit is Medfield’s ongoing collaboration with the Hunter Medical Research Institute, which includes clinical verification of Medfield’s MD100 system.
Great interest when Medfield participates in the ESOC and Vitalis conferences.
